StemCells, Inc. has announced that three of its senior executives and a key academic research collaborator are scheduled to present at the 2011 World Stem Cell Summit scheduled for October 3-5, 2011 at the Pasadena Convention Center, Pasadena, California.
The World Stem Cell Summit is the global stem cell and regenerative medicine community’s leading event, and allows scientists, patients, advocates, business people, investors, educators, ethicists, policy makers, and government representatives from around the world to meet, share knowledge and collaborate with others in the field.
Ann Tsukamoto, Ph.D., Executive Vice President, Research & Development of StemCells, Inc., will be a featured speaker during a plenary discussion on “How Stem Cells Are Transforming Medicine - ISSCR Perspectives,” which is scheduled for 9:00 am PT on Monday, October 3.
Aileen Anderson, Ph.D., a professor at the University of California, Irvine, will speak during a session on “Stem Cell Translational Report - Spinal Cord Injury, Paralysis and MS,” which is scheduled to begin at 2:30 pm PT on Tuesday, October 4.
Dr. Anderson has collaborated with the Company to publish numerous preclinical studies to demonstrate the therapeutic potential of the Company’s human neural stem cells for the treatment of spinal cord injury.
Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. will be a featured speaker during a session on “Promising Science from Industry Labs.” This session is scheduled to begin at 1:00 pm PT on Wednesday, October 5.
Martin McGlynn, President and CEO of StemCells, Inc., will discuss the Company’s clinical development program during a session on “Key Clinical Trial Updates,” which is scheduled to begin at 2:00 pm PT on Wednesday, October 5.
The Company is currently conducting two clinical trials of its HuCNS-SC® cells, one in chronic spinal cord injury and one in a myelination disorder in the brain.
The multiple presentations by the Company’s executives and collaborator highlight the scientific achievements and progress in advancing novel discoveries to potential therapeutic applications.
StemCells, Inc. is pleased to be an integral part of this important and rapidly growing event and to have the opportunity to interact with researchers, clinicians, and patients with an interest in novel stem cell-based approaches to intractable neurodegenerative diseases.